# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Ross Osborn reiterates VolitionRX (AMEX:VNRX) with a Overweight and maintains $2.5 price target.
EF Hutton analyst Tim Moore maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $4.5 price target.
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 15.38...
Financial HighlightsCash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9...
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on re...